The lawyer Rūta Pumputienė prepared a commentary “Avoiding the repetition of Sicor Biotech’s story” for the business daily Verslo žinios.
“The representative of the international generic giant TEVA in Lithuania – Sicor Biotech – closed its R&D unit in Vilnius, after receiving annual orders valued at 1.4 mln. EUR. In this particular case, the Lithuanian authorities cannot be blamed, but if we are declaring plans to become a hub for the Life Sciences we do not have the luxury of sitting still,” wrote R. Pumputienė in the commentary.
Read more in Lithuanian at: https://www.vz.lt/verslo-aplinka/2017/08/24/kad-sicor-biotech-istorija-nesikartotu#ixzz5OoglqgmF